- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05742763
Platelet-Rich Plasma and the Effects of NSAIDs on Pain and Functional Scores in Knee Osteoarthritis (PRPNSAIDsKOA)
Study Overview
Status
Detailed Description
For this 5-year Research Project, the investigators propose to implement a prospective, double-blind, three-arm randomized placebo controlled clinical trial study design across multiple clinic sites in North Carolina and South Carolina. The primary research purpose is to determine if the use of ibuprofen [arm #1] vs acetaminophen [arm #2] vs a placebo control group [arm #3] with the intervention of a series of three injections of leukocyte poor platelet-rich plasma (LP-PRP) into the knee joint, leads to significantly greater reductions in average knee pain severity, and increases in physical function and quality of life, in patients with symptomatic moderate knee osteoarthritis (KOA), and grade 2 or 3 radiographic changes defined by the Kellgren-Lawrence (K-L) classification system. Data collected as part of the PRP-NSAIDs-KOA Trial will be used to: 1) inform the treatment of patients with moderate KOA using the orthobiologic PRP; 2) assess the use of ibuprofen vs acetaminophen vs placebo by serially evaluating pain score outcomes and functionality using standardized and validated pain subscales (Visual Analogue Scale (VAS), Western Ontario McMaster Universities Osteoarthritis Index (WOMAC), Knee injury and Osteoarthritis Outcomes Score (KOOS), and the International Knee Documentation Committee (IKDC) in patients with moderate KOA randomized to three arms; and 3) assess and compare serial changes in composition of whole blood and PRP with the use of ibuprofen vs acetaminophen vs placebo. The investigators will also assess the clinical trial protocol process measures of feasibility, acceptability, and implementation to evaluate and improve multi-site clinical trial delivery at QC Kinetix clinic sites.
The central hypothesis of the study is that patients receiving ibuprofen will initially report higher VAS, WOMAC, KOOS, and IKDC pain scores at each 1-month post-treatment follow up, with a return to baseline and progressively lower pain scores at each subsequent follow up visit when compared to patients in the other two arms. The long-term goal of this research study is to build the QC Kinetix workforce clinical research capacity in the conduct of sports and regenerative medicine related multi-site clinical trials and apply for the American Medical Society for Sports Medicine (AMSSM) Foundation Research Grant, the American College of Sports Medicine (ACSM) Research Grant, the Arthritis Society Research Grant, and the AMSSM Collaborative Research Network (CRN) Grant that builds on lessons learned from this research effort. The investigators will successfully achieve the primary research goal of this research study through the following four specific aims
Aim #1: During ongoing recruitment and enrollment, the investigators will identify and recruit patients with moderate KOA seen across new and established patients attending QC Kinetix clinic sites (i.e., North and South Carolina).
o H1-1: Based on our clinic data, the investigators expect patients on daily NSAIDs to have increased symptoms of pain and reduced function during the washout period of 1 month (all study participants must discontinue all analgesic medications including acetaminophen and NSAIDs) prior to the series of PRP injections.
Aim #2. Design and implement a prospective, 5-year double-blinded, three-arm randomized clinical trial study design across multiple QC Kinetix clinic sites (i.e., North and South Carolina) to compare VAS, WOMAC, KOOS, and IKDC pain and function subscale scores at baseline and follow-up visits at months 1, 2, 3, (drug therapy, PRP, and completion of pain subscales); months 4, and 6 (drug therapy and pain subscales) and months 9 and 12 (pain subscales only) post-enrollment and treatment following the initiation of the 3 PRP injections in all three groups [arm #1-3] in patients with symptomatic moderate KOA (K-L grade 2 or 3).
o H2-1: Patients who receive ibuprofen will initially report higher VAS, WOMAC, KOOS, and IKDC pain scores at each 1-month post-treatment follow up, with a return to baseline and progressively lower pain scores at each subsequent follow up visit when compared to patients in the other two arms.
Aim #3: Assess and compare changes in platelet count in the whole blood and PRP of all study participants at each clinic visit.
Aim #4: Evaluate process measures (i.e., feasibility, acceptability, and implementation) for clinical trial protocol success between and within all QC Kinetix clinic sites.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Kenneth P Barnes, MD, MSc.
- Phone Number: 3365890721
- Email: kbarnes@qckinetix.com
Study Contact Backup
- Name: Richard S Schaffer, MD
- Phone Number: 8432760185
- Email: drschaffer@qckinetix.com
Study Locations
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28211
- Recruiting
- QC Kinetix Franchise Group, LLC, 309 South Sharon Amity Rd, Ste 302
-
Contact:
- Kenneth P Barnes, MD
- Phone Number: 336-589-0721
- Email: kbarnes@qckinetix.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age >50 (all genders, and all races)
- Unilateral Symptoms
- Symptomatic knee pain on most days in the past month
- OA diagnosed with radiographic imaging (K-L grade 2 or 3)
- Can commit to 8 office visits (initial and 7 follow up) over a 12-month period
- Able to understand written/spoken English - all study participants will be provided with an overview of the study goals, research activities and tasks, and an opportunity to address any questions, comments, or concerns about their participation in the PRP_NSAIDs-PRP research trial. After which, written informed consent and HIPPA Research Disclosure form will be obtained.
Exclusion Criteria:
- K-L grade 1 (indicting questionable disease) or grade 4 (indicating severe disease)
- Have lateral joint space narrowing greater than or equal to medial joint space narrowing on x-ray using the Osteoarthritis Research Society International (OARSI) atlas
- Had injection into the target knee joint of glucocorticoid in the past 3 months or hyaluronic acid in the past 6 months
- Had any autologous blood product or stem cell preparation in the past
- Had knee surgery on their target knee within the past 12 months
- Have systemic or inflammatory joint disease such as rheumatoid arthritis
- Have a history of crystalline or neuropathic arthropathy
- Had a knee joint replacement or high tibial osteotomy on their target knee
- Plan to have knee surgery in the target knee in next 12 months
- Have other muscular, joint, or neurological condition affecting lower limb function
- Osteonecrosis, avascular necrosis
- Gastrointestinal reflux disease or peptic ulcer disease
- NSAID intolerance
- Renal dysfunction or liver disease
- Previous gastric bypass surgery
- Have a needle phobia
- Have immunosuppression or acute infective processes
- Have cancer or other tumors in the last 3 years, or undergone any treatment for cancer or tumors in the last 3 years
- Have a bleeding disorder or are receiving anticoagulation therapy
- Have the presence of a warm, tense joint effusion
- Have a platelet count < 150,000/μL
- Have any other medical condition precluding participation in the study
- Pregnancy
- Are unwilling to discontinue any use of an NSAID, acetaminophen, and other analgesic usage, from 1 month before the baseline assessment until the last follow-up assessment at month 12
- Have a body mass index (BMI) > 40 kg/m2
- Have a weight ≤ 100 pounds
- Unable to attend all study appointments (initial visit and 7 follow up visits) over 12 months
- Cannot understand written/spoken English
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Ibuprofen and PRP
Weight based Ibuprofen provided in over-encapsulated blister pack (to ensure blinding), to be taken 3 times a day for the initial 6 months of the 12 month study period.
PRP injections provided at month 1, 2, and 3.
|
The primary research purpose is to determine if the use of ibuprofen [arm #1] vs acetaminophen [arm #2] vs a placebo control group [arm #3] with the intervention of a series of three injections of LP-PRP into the knee joint, leads to significantly greater reductions in average knee pain severity, and increases in physical function and quality of life, in patients with symptomatic moderate KOA, and grade 2 or 3 radiographic changes defined by the Kellgren-Lawrence (K-L) classification system.
|
Active Comparator: Acetaminophen and PRP
Weight based Acetaminophen provided in over-encapsulated blister pack (to ensure blinding), to be taken 3 times a day for the initial 6 months of the 12 month study period.
PRP injections provided at month 1, 2, and 3.
|
The primary research purpose is to determine if the use of ibuprofen [arm #1] vs acetaminophen [arm #2] vs a placebo control group [arm #3] with the intervention of a series of three injections of LP-PRP into the knee joint, leads to significantly greater reductions in average knee pain severity, and increases in physical function and quality of life, in patients with symptomatic moderate KOA, and grade 2 or 3 radiographic changes defined by the Kellgren-Lawrence (K-L) classification system.
|
Placebo Comparator: Placebo and PRP
Placebo provided in over-encapsulated blister pack (to ensure blinding), to be taken 3 times a day for the initial 6 months of the 12 month study period.
PRP injections provided at month 1, 2, and 3.
|
The primary research purpose is to determine if the use of ibuprofen [arm #1] vs acetaminophen [arm #2] vs a placebo control group [arm #3] with the intervention of a series of three injections of LP-PRP into the knee joint, leads to significantly greater reductions in average knee pain severity, and increases in physical function and quality of life, in patients with symptomatic moderate KOA, and grade 2 or 3 radiographic changes defined by the Kellgren-Lawrence (K-L) classification system.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
VAS pain scores after combination interventions of blinded medication therapy and a series of 3 PRP injections.
Time Frame: Scores obtained and assessed for a change at each office visit - at baseline (time 0), month 1, 2, 3, 4, 6, 9 and 12.
|
The investigators will obtain standardized and validated pain scores.
The first is the VAS.
The scale is 0-10.
0 is "no pain" and 10 is "unbearable pain".
|
Scores obtained and assessed for a change at each office visit - at baseline (time 0), month 1, 2, 3, 4, 6, 9 and 12.
|
WOMAC pain and functionality scores after combination interventions of blinded medication therapy and a series of 3 PRP injections.
Time Frame: Scores obtained and assessed for a change at each office visit - at baseline (time 0), month 1, 2, 3, 4, 6, 9 and 12.
|
The investigators will obtain standardized and validated pain scores.
The second is the WOMAC.
The scale is 0-96.
0 is "no pain and no loss of function" and 96 is "unbearable pain and complete loss of function".
|
Scores obtained and assessed for a change at each office visit - at baseline (time 0), month 1, 2, 3, 4, 6, 9 and 12.
|
KOOS pain and functionality scores after combination interventions of blinded medication therapy and a series of 3 PRP injections.
Time Frame: Scores obtained and assessed for a change at each office visit - at baseline (time 0), month 1, 2, 3, 4, 6, 9 and 12.
|
The investigators will obtain standardized and validated pain scores.
The third is the KOOS.
The scale is 0-100.
0 is "no pain and no loss of function" and 100 is "unbearable pain and complete loss of function".
|
Scores obtained and assessed for a change at each office visit - at baseline (time 0), month 1, 2, 3, 4, 6, 9 and 12.
|
IKDC pain and functionality scores after combination interventions of blinded medication therapy and a series of 3 PRP injections.
Time Frame: Scores obtained and assessed for a change at each office visit - at baseline (time 0), month 1, 2, 3, 4, 6, 9 and 12.
|
The investigators will obtain standardized and validated pain scores.
The fourth is the IKDC.
The scale is 0-100.
100 is "no pain and no loss of function" and 0 is "unbearable pain and complete loss of function".
|
Scores obtained and assessed for a change at each office visit - at baseline (time 0), month 1, 2, 3, 4, 6, 9 and 12.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kenneth P Barnes, MD, MSc., QC Kinetix LLC
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Arthritis
- Osteoarthritis
- Osteoarthritis, Knee
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Antipyretics
- Acetaminophen
- Ibuprofen
Other Study ID Numbers
- PRP-NSAIDs-KOA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis of the Knee
-
Taiwan Liposome CompanyCompletedOSTEOARTHRITIS OF THE KNEETaiwan, United States
-
University Hospital, GhentCompletedOsteoarthritis of the Knee JointBelgium
-
Bone Therapeutics S.ANordic Bioscience A/SCompletedSymptomatic Osteoarthritis of the KneeDenmark, Belgium, United Kingdom, Czechia, Hong Kong, Moldova, Republic of, Poland
-
Rush University Medical CenterWithdrawnSymptomatic Osteoarthritis of the Knee
-
Region SkaneRecruitingOsteoarthritis of the Knee or HipSweden
-
UMC UtrechtCompletedMedial Compartment Osteoarthritis of the KneeNetherlands
-
Massachusetts General HospitalGöteborg University; Seoul National University Hospital; Ulsan University Hospital and other collaboratorsUnknownOsteoarthritis of the Knee | Traumatic Arthritis of the KneeUnited States
-
Ampio Pharmaceuticals. Inc.TerminatedSevere Osteoarthritis of the KneeUnited States
-
Ampio Pharmaceuticals. Inc.TerminatedSevere Osteoarthritis of the KneeUnited States
-
Hospital General de Jerez de la FronteraZiekenhuis Oost-LimburgCompletedPainful Osteoarthritis of the KneeSpain
Clinical Trials on Ibuprofen and PRP
-
Sun Yat-sen UniversityUnknownSevere Non-proliferative Diabetic RetinopathyChina
-
Ankara Universitesi TeknokentCompleted
-
Heba Mohamed Saad EldienM.A. Eloteify; Ahmed Kamal Osman; G.M. HafsaCompleted
-
National Defense Medical Center, TaiwanTri-Service General HospitalRecruitingAnkle Sprain 2Nd Degree | Ankle Sprain 3Rd DegreeTaiwan
-
Postgraduate Institute of Dental Sciences RohtakUnknownPeriapical Lesions
-
Arteriocyte, Inc.TerminatedDiabetic Foot Ulcers | Pressure Ulcers | Venous UlcersUnited States
-
Cairo UniversityRecruiting
-
University of Colorado, DenverTerumo BCTCompletedOsteochondritis DissecansUnited States
-
Shin Kong Wu Ho-Su Memorial HospitalMinistry of Science and Technology, TaiwanCompletedPRP Injection Only | Physiotherapy Only | PRP and PhysiotherapyTaiwan
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingDry Age-related Macular DegenerationItaly